Strategic Focus Immunic, Inc. (formerly Vital Therapies) is a late-stage biotechnology company with ongoing Phase 2 and Phase 3 programs in neurology and MS, presenting opportunities for partnerships, licensing, or co-development of complementary assets and services to accelerate their clinical timelines.

Financial Scale With a funding base of approximately $228 million and recent $400 million financing aimed at completing Phase 3 MS programs and launch readiness, there is potential for vendors and CROs, contract research, and manufacturing partners to support scale-up and regulatory activities.

Leadership Momentum Significant executive appointments and board leadership changes in 2026 signal a strategic inflection point, creating opportunities for advisory services, investor relations support, and strategic collaborations with new governance that value robust project governance and commercialization planning.

Clinical Trajectory Active communication around Phase 2 CALLIPER data and upcoming Phase 3 MS readouts suggests demand for specialized clinical analytics, imaging, patient recruitment optimization, and real-world evidence partnerships to strengthen regulatory submissions.

Market Position Operating in neurology with potential for rapid advancement, Immunic targets a high-growth, capital-intensive segment where CROs, manufacturing partners, and specialty suppliers can offer scalable services aligned to late-stage trials, launch readiness, and payer-facing strategies.